Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study

Published:2024-09-12 Issue: Volume: Page:1-9
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Carrión-Madroñal Isabel María¹^ORCID,Díaz-Acedo Rocío²^ORCID,Lora-Escobar Santiago José²^ORCID,Naranjo-Llamas Eloisa³,Jaramillo-Ruiz Didiana²^ORCID,Artacho-Criado Silvia³^ORCID,Prado-Mel Elena²^ORCID

Affiliation:

1. Servicio de Farmacia, Hospital Universitario Virgen Macarena, Seville, 41009, SPAIN

2. Servicio de Farmacia, Hospital Universitario Virgen del Rocío, Seville, 41013, SPAIN

3. Servicio de Farmacia, Hospital Universitario Virgen de Valme, Seville, 41014, SPAIN

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2394408

Reference28 articles.

1. Global Cancer Observatory;GLOBOCAN 2020;Int Agency Res Cancer.,2024

2. Prognostic factors for early relapse in non-metastatic triple negative breast cancer — real world data

3. Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

4. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review

5. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP